Abstract
Remarkable efficacy has been achieved in a variety of cancer types by targeting immune checkpoints. The cytotoxic T-lymphocyte–associated antigen 4 inhibitor ipilimumab, the programmed death 1 inhibitors nivolumab and pembrolizumab, and the programmed death ligand 1 inhibitors atezolizumab, avelumab, and durvalumab are the agents currently approved by the US Food and Drug Administration for the treatment of certain advanced malignancies. These agents mark a departure from both standard cytotoxic chemotherapy and targeted therapy. However, they are associated with a unique set of immune-related adverse events (irAEs), which can manifest as a wide range of autoimmune phenomena. The irAEs can affect any system in the body and in rare cases are life-threatening. It is critical for the practicing medical oncologist to recognize and promptly treat any irAEs that may develop.
| Original language | English |
|---|---|
| Pages (from-to) | 364-374 |
| Number of pages | 11 |
| Journal | Clinical Advances in Hematology and Oncology |
| Volume | 16 |
| Issue number | 5 |
| State | Published - May 2018 |
Keywords
- Antibodies, Monoclonal, Humanized/administration & dosage
- Antibodies, Monoclonal/administration & dosage
- Antineoplastic Agents/administration & dosage
- B7-H1 Antigen/antagonists & inhibitors
- CTLA-4 Antigen/antagonists & inhibitors
- Colitis/etiology
- Dermatitis/etiology
- Disease Management
- Gene Expression Regulation, Neoplastic/immunology
- Hematologic Neoplasms/drug therapy
- Hepatitis/etiology
- Humans
- Immunotherapy/adverse effects
- Ipilimumab/administration & dosage
- Nivolumab
- Pneumonia/etiology
- Programmed Cell Death 1 Receptor/antagonists & inhibitors